A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children

Clinical Pharmacokinetics

Volumn 53, Issue 12, 2014, Pages 1171-1182

  Zane, Nicole R ^a   Thakker, Dhiren R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE; ANTIFUNGAL AGENT;

ABSORPTION RATE CONSTANT; ADULT; ARTICLE; CHILD; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; FIRST PASS EFFECT; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CLEARANCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACTIVITY ASSAY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PKA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; INTESTINE; METABOLISM; NORMAL HUMAN; PRESCHOOL CHILD; REPRODUCIBILITY;

ADULT; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTESTINES; MALE; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; VORICONAZOLE;

EID: 84922076428     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0181-y     Document Type: Article

References (45)

1. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis. 2005;18(6):484–9.
2. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15. doi:10.1056/NEJMoa020191.
3. Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55(12):5770–9. doi:10.1128/AAC.00531-11.
4. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53(3):935–44. doi:10.1128/AAC.00751-08.
5. Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23. doi:10.1128/AAC.00896-10.
6. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–72. doi:10.1128/AAC.48.6.2166-2172.2004.
7. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006;27(4):274–84. doi:10.1016/j.ijantimicag.2006.01.003.
8. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med. 2005;10(2):123–38. doi:10.1016/j.siny.2004.11.001.
9. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67. doi:10.1056/NEJMra035092.
10. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965–74. doi:10.1124/jpet.103.060137.
11. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307(2):573–82. doi:10.1124/jpet.103.054841.
12. Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38(1):25–31. doi:10.1124/dmd.109.029769.
13. Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother. 2011;55(2):925–8. doi:10.1128/AAC.00949-10.
14. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Annal ICRP. 2002;32(3–4):5–265.
15. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59(6):691–704. doi:10.1111/j.1365-2125.2004.02225.x.
16. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546–53.
17. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003;56(Suppl 1):17–23.
18. Jones HM, Gardner IB, Watson KJ. Modelling and PBPK simulation in drug discovery. AAPS J. 2009;11(1):155–66. doi:10.1208/s12248-009-9088-1.
19. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies: 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56.
20. Damle B, Varma MV, Wood N. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother. 2011;55(11):5172–7. doi:10.1128/AAC.00423-11.
21. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol. 2007;3(4):573–81. doi:10.1517/17425225.3.4.573.
22. Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos. 2012. doi:10.1002/bdd.1830.
23. Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, et al. Effect of CYP2c19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2011. doi:10.1177/0091270010395510.
24. Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–15. doi:10.1111/j.1365-2125.2009.03534.x.
25. Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196–204. doi:10.1177/0091270008327537.
26. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handbook Exp Pharmacol. 2011;205:51–75. doi:10.1007/978-3-642-20195-0_2.
27. Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57(1):235–40. doi:10.1128/AAC.01540-12.
28. Doby EH, Benjamin DK Jr, Blaschke AJ, Ward RM, Pavia AT, Martin PL, et al. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J. 2012;31(6):632–5. doi:10.1097/INF.0b013e31824acc33.
29. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metabol Dispos. 2003;31(5):540–7.
30. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metabol Dispos. 2003;31(6):731–41.
31. Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK Jr, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metabol Dispos. 2008;36(6):1119–25. doi:10.1124/dmd.107.019646.
32. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338(8781):1488–90.
33. Fakhoury M, Litalien C, Medard Y, Cave H, Ezzahir N, Peuchmaur M, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metabol Dispos. 2005;33(11):1603–7. doi:10.1124/dmd.105.005611.
34. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 “pie”. Drug Metabol Dispos. 2006;34(5):880–6. doi:10.1124/dmd.105.008672.
35. Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol. 2001;51(5):451–60.
36. Berseth CL. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr. 1989;115(4):646–51.
37. Bisset WM, Watt JB, Rivers RP, Milla PJ. Ontogeny of fasting small intestinal motor activity in the human infant. Gut. 1988;29(4):483–8.
38. Gupta M, Brans YW. Gastric retention in neonates. Pediatrics. 1978;62(1):26–9.
39. Heimann G. Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol. 1980;18(1):43–50.
40. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032–42. doi:10.1128/AAC.05761-11.
41. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50–61. doi:10.1038/clpt.2012.65.
42. Benjamin DK Jr, Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51(4):834–40. doi:10.1161/HYPERTENSIONAHA.107.108886.
43. Jadhav PR, Zhang J, Gobburu JV. Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study. Pharm Stat. 2009;8(3):216–24. doi:10.1002/pst.394.
44. Salazar DE, Song SH, Shi J, Rohatagi S, Heyrman R, Wada DR, et al. The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects. Clin Pharmacol Ther. 2012;91(2):250–6. doi:10.1038/clpt.2011.220.
45. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD, et al. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. CPT: Pharmacomet Syst Pharmacol. 2012;1:e3–256. doi:10.1038/psp.2012.2.